FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049672489> ?p ?o ?g. }

• W2049672489 endingPage "931" @default.
• W2049672489 startingPage "925" @default.
• W2049672489 abstract "Bombesin receptor subtype-3 (BRS-3) is an orphan G-protein-coupled receptor (GPCR) member of the bombesin receptor family. Several studies have suggested an association between obesity, alterations in glucose metabolism, diabetes and the BRS-3 receptor. In this study, we focused on patients simultaneously diagnosed with obesity and type 2 diabetes (OB/T2D). The analysis of BRS-3 expression in the skeletal muscle of these patients revealed a marked decrease in the expression of BRS-3 at the mRNA (23.6±1.3-fold downregulation, p<0.0001) and protein level (49±7% decrease, p<0.05) compared to the normal patients (no obesity and diabetes). Moreover, in cultured primary myocytes from patients with OB/T2D, the synthetic BRS-3 agonist, [D-Try6,β‑Ala11,Phe13,Nle14]bombesin6-14, significantly increased the phosphorylation levels of mitogen-activated protein kinase (MAPK), p90RSK1, protein kinase B (PKB) and p70s6K. Specifically, the ligand at 10-11 M induced the maximal phosphorylation of MAPKs (p42, 159±15% of the control; p44, 166±11% of the control; p<0.0001) and p90RSK1 (148±2% of the control, p<0.0001). The basal phosphorylation levels of all kinases were reduced (p<0.05) in the patients with OB/T2D compared to the normal patients. Furthermore, the BRS-3 agonist stimulated glucose transport, which was already detected at 10-12 M (133±9% of the control), reached maximal levels at 10-11 M (160±9%, p<0.0001) and was maintained at up to 10-8 M (overall mean, 153±7%; p<0.007). This effect was less promiment than that attained with 10-8 M insulin (202±9%, p=0.009). The effect of the agonist on glycogen synthase a activity achieved the maximum effect at 10-11 M (165±16% of the control; p<0.0001), which did not differ from that observed with higher concentrations of the agonist. These results suggest that muscle cells isolated from patients with OB/T2D have extremely high sensitivity to the synthetic ligand, and the effects are particularly observed on MAPK and p90RSK1 phosphorylation, as well as glucose uptake. Moreover, our data indicate that BRS-3 may prove to be useful as a potential therapeutic target for the treatment of patients with OB/T2D." @default.
• W2049672489 created "2016-06-24" @default.
• W2049672489 creator A5005804630 @default.
• W2049672489 creator A5018758536 @default.
• W2049672489 creator A5032709251 @default.
• W2049672489 creator A5035733707 @default.
• W2049672489 creator A5051719052 @default.
• W2049672489 creator A5053070199 @default.
• W2049672489 creator A5055586530 @default.
• W2049672489 date "2015-02-04" @default.
• W2049672489 modified "2023-09-26" @default.
• W2049672489 title "Effect of bombesin receptor subtype-3 and its synthetic agonist on signaling, glucose transport and metabolism in myocytes from patients with obesity and type 2 diabetes" @default.
• W2049672489 cites W1509317138 @default.
• W2049672489 cites W1537449868 @default.
• W2049672489 cites W1545856647 @default.
• W2049672489 cites W1893274404 @default.
• W2049672489 cites W1964378827 @default.
• W2049672489 cites W1965602606 @default.
• W2049672489 cites W1978349701 @default.
• W2049672489 cites W1979133715 @default.
• W2049672489 cites W1981770260 @default.
• W2049672489 cites W1995870854 @default.
• W2049672489 cites W1996547261 @default.
• W2049672489 cites W2009128783 @default.
• W2049672489 cites W2018289835 @default.
• W2049672489 cites W2020039911 @default.
• W2049672489 cites W2032845306 @default.
• W2049672489 cites W2034196521 @default.
• W2049672489 cites W2036587772 @default.
• W2049672489 cites W2036678616 @default.
• W2049672489 cites W2044693162 @default.
• W2049672489 cites W2052036447 @default.
• W2049672489 cites W2052224391 @default.
• W2049672489 cites W2062367689 @default.
• W2049672489 cites W2075830220 @default.
• W2049672489 cites W2076718788 @default.
• W2049672489 cites W2076805031 @default.
• W2049672489 cites W2083905313 @default.
• W2049672489 cites W2100837269 @default.
• W2049672489 cites W2107277218 @default.
• W2049672489 cites W2107794104 @default.
• W2049672489 cites W2137848795 @default.
• W2049672489 cites W2140366278 @default.
• W2049672489 cites W2141171363 @default.
• W2049672489 cites W2145661651 @default.
• W2049672489 cites W2148624282 @default.
• W2049672489 cites W2192080449 @default.
• W2049672489 cites W2054233951 @default.
• W2049672489 doi "https://doi.org/10.3892/ijmm.2015.2090" @default.
• W2049672489 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4356436" @default.
• W2049672489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25653074" @default.
• W2049672489 hasPublicationYear "2015" @default.
• W2049672489 type Work @default.
• W2049672489 sameAs 2049672489 @default.
• W2049672489 citedByCount "11" @default.
• W2049672489 countsByYear W20496724892015 @default.
• W2049672489 countsByYear W20496724892017 @default.
• W2049672489 countsByYear W20496724892018 @default.
• W2049672489 countsByYear W20496724892019 @default.
• W2049672489 countsByYear W20496724892021 @default.
• W2049672489 countsByYear W20496724892022 @default.
• W2049672489 countsByYear W20496724892023 @default.
• W2049672489 crossrefType "journal-article" @default.
• W2049672489 hasAuthorship W2049672489A5005804630 @default.
• W2049672489 hasAuthorship W2049672489A5018758536 @default.
• W2049672489 hasAuthorship W2049672489A5032709251 @default.
• W2049672489 hasAuthorship W2049672489A5035733707 @default.
• W2049672489 hasAuthorship W2049672489A5051719052 @default.
• W2049672489 hasAuthorship W2049672489A5053070199 @default.
• W2049672489 hasAuthorship W2049672489A5055586530 @default.
• W2049672489 hasBestOaLocation W20496724891 @default.
• W2049672489 hasConcept C104317684 @default.
• W2049672489 hasConcept C11960822 @default.
• W2049672489 hasConcept C126322002 @default.
• W2049672489 hasConcept C127561419 @default.
• W2049672489 hasConcept C134018914 @default.
• W2049672489 hasConcept C170493617 @default.
• W2049672489 hasConcept C184235292 @default.
• W2049672489 hasConcept C185592680 @default.
• W2049672489 hasConcept C2777180221 @default.
• W2049672489 hasConcept C2778938600 @default.
• W2049672489 hasConcept C55493867 @default.
• W2049672489 hasConcept C555293320 @default.
• W2049672489 hasConcept C57074206 @default.
• W2049672489 hasConcept C71924100 @default.
• W2049672489 hasConcept C75217442 @default.
• W2049672489 hasConcept C86803240 @default.
• W2049672489 hasConceptScore W2049672489C104317684 @default.
• W2049672489 hasConceptScore W2049672489C11960822 @default.
• W2049672489 hasConceptScore W2049672489C126322002 @default.
• W2049672489 hasConceptScore W2049672489C127561419 @default.
• W2049672489 hasConceptScore W2049672489C134018914 @default.
• W2049672489 hasConceptScore W2049672489C170493617 @default.
• W2049672489 hasConceptScore W2049672489C184235292 @default.
• W2049672489 hasConceptScore W2049672489C185592680 @default.
• W2049672489 hasConceptScore W2049672489C2777180221 @default.
• W2049672489 hasConceptScore W2049672489C2778938600 @default.
• W2049672489 hasConceptScore W2049672489C55493867 @default.

• next